Hematogenix
Hematogenix, a leading provider in the field of laboratory services, is headquartered in Great Britain and operates extensively across Europe and North America. Founded in 1997, the company has established itself as a trusted name in the diagnostics industry, specialising in advanced laboratory testing and pathology services. With a focus on oncology, infectious diseases, and genetic testing, Hematogenix offers a unique blend of innovative technologies and expert analysis. Their commitment to quality and precision has earned them a strong market position, recognised for their comprehensive testing solutions that cater to both clinical and research needs. Notable achievements include the development of proprietary testing methodologies that enhance diagnostic accuracy, solidifying Hematogenix's reputation as a pioneer in the laboratory services sector.
DitchCarbon Score
How does Hematogenix's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hematogenix's score of 6 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hematogenix's reported carbon emissions
Hematogenix Laboratory Services, headquartered in Great Britain, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. Although specific emissions data for the most recent year is not available, the company has established a target to reduce its Scope 1 and Scope 2 emissions by 42% by the year 2030, using 2023 as the baseline year. This target has been validated through the Science Based Targets initiative (SBTi), ensuring alignment with the global goal of limiting temperature rise to 1.5°C. In addition to its focus on direct emissions (Scope 1) and indirect emissions from energy consumption (Scope 2), Hematogenix is also committed to measuring and reducing its Scope 3 emissions, which encompass the broader impact of its value chain. These initiatives reflect the company's dedication to sustainability within the healthcare sector, positioning it as a responsible player in the fight against climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hematogenix is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
